Oxygen Biotherapeutics contracts with U.S. Navy, continued ...
The Navy and the Virginia Commonwealth University Reanimation Shock Center, Oxygen's primary research partner, have a $3.8 million budget for the study of perfluorocarbon therapeutic oxygen carriers. It's welcome news for the company, which doesn't have the funding itself, says Stern.
There is no proven adjunct therapy – or treatments used in conjunction with the primary one – for decompression sickness and arterial gas embolism, he continues. But if the research is met with success and the Navy gets FDA approval, Oxygen could have the option to license the rights from the findings.
Oxygen Biotherapeutics is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and defense medicine. << PREVIOUS PAGE